Recent research on the formation and maintenance of the vasculature in the embryo and in the adult has provided a greater understanding of the cellular signals involved in these processes. With this understanding comes the potential means of controlling vascularization in pathological situations such as tumorigenesis and wounding. For the purpose of this review, we will discuss the key receptor tyrosine kinases involved in vascular function and the molecules which relay signals downstream of receptor activation. The receptor tyrosine kinases discussed include the vascular endothelial cell growth factor receptors, Eph receptors, Tie1, and Tie2, all of which are expressed on vascular endothelial cells. We also discuss the roles of the platelet derived growth factor receptors which are expressed on vascular smooth muscle cells. While all of these receptor tyrosine kinases activate many similar eector molecules, some of the signals initiated appear to be distinct. This may explain, at least in part, how dierent receptor tyrosine kinases expressed in overlapping patterns on the developing vasculature, direct unique biological functions.
Introduction
The vasculature is one of the ®rst systems to form in the embryo, and its proper con®guration is required to allow further development. Because the emphasis of this review is on the signaling events following activation of vascular receptor tyrosine kinases (RTKs), only a brief discussion of vascular development is provided here. Many recent reviews discuss the assembly of blood vessels, and we would refer the reader to these for a more detailed discussion Korpelainen and Alitalo, 1998; Risau, 1995 Risau, , 1997 . The yolk sac is the initial site of primitive vessel formation and is the destination of the hemangioblast, the proposed precursor of both hematopoeitic and endothelial cells derived from the embryonic mesoderm. In the yolk sac, the hemangioblasts form clumps called blood islands. The outer cells of the blood islands dierentiate into endothelial cells (angioblasts) and the inner cells into hematopoeitic precursors. Vascular endothelial cell growth factor receptor-2 (VEGFR-2) is an endothelial cell-speci®c RTK found in the blood islands beginning at embryonic day 7 (E7) (Kaipainen et al., 1993; Yamaguchi et al., 1993) . VEGFR-2 may be responsible for directing individual angioblasts to migrate and coalesce, forming the primitive tubular vessels. This de novo vessel formation is termed vasculogenesis. Another VEGFR family member, VEGFR-1, is detected in these primitive endothelial cells (Peters et al., 1993) beginning at E8. Both VEGFR-1 and -2 respond to the ligand, VEGFA, which is found in cells adjacent to the developing endothelial cells, indicating a paracrine mechanism for endothelial cell establishment (Breier et al., 1992) . A similar procedure with VEGFR positive endothelial cells occurs in the embryo proper to form the primary capillary plexus and vasculature of the endodermally derived organs (Millauer et al., 1993; Peters et al., 1993; . The third family member, VEGFR-3, may also promote vascularization. It is expressed at E8 in angioblasts of the head and cardinal veins, but then becomes restricted to the lymphatic vessels (Kaipainen et al., 1995) .
In the next morphological change, the preexisting vessels are remodeled by pruning, branching, and sprouting. The formation of new vessels from existing vessels is the process of angiogenesis. It is during these later processes that the Tie and Eph receptors are believed to play roles. Tie2 is expressed in angioblasts as early as E7 , and Tie1 can be found a day later (Korhonen et al., 1994; Partanen et al., 1992) . The ligands for Tie2 (angiopoietin-1 and 2 [Ang1 and Ang2]) are expressed in overlapping but not identical regions. While Ang2 is often found in a punctate staining pattern, both are expressed in mesenchyme and/or smooth muscle cells (SMC) surrounding the growing vessels Maisonpierre et al., 1997) . As the developing vasculature matures, a PDGFRb-expressing mesenchyme layer forms next to the endothelial cell layer, which expresses PDGFB, the sole ligand for the PDGFRb (Hellstrom et al., 1999; Holmgren et al., 1991; Shinbrot et al., 1994) . These PDGFRb positive cells mature into vascular smooth muscle cells (VSMC) or pericytes. The mature VSMC express contractile proteins, provide support to the vessel, and regulate vasoconstriction.
In the ®nal maturation stage, a distinction is made between the arterial and venous vasculature. Previously, histology and blood¯ow were used to distinguish arteries from veins, but recently several groups have observed Eph receptors and their ligands, the ephrins, in restricted vascular locations. For example, ephrinB2 is found exclusively on arterial endothelial cells, while EphB4 is expressed only on venous endothelial cells (Wang et al., 1998) . Others have found that, unlike the aforementioned ligand and receptor, ephrin B1, EphB2 and EphB3 are expressed across arterial and venous endothelial cells and in the mesenchyme (Adams et al., 1999) . Ephrin A1 also appears to be expressed in both venous and arterial cells (McBride and Ruiz, 1998) , suggesting that both classes of ephrins may direct cell localization during vascular development. The development of the vasculature is obviously a complex process with intricate cellular regulation both within a cell type and between adjoining cells. As discussed below and illustrated in Figure 1 , gene disruption experiments have revealed that the RTKs expressed in the vasculature play key roles in the generation of blood vessels. We will now discuss how these signals may be transmitted into the cell via eector molecules.
VEGFR signal transduction
Ligand binding and receptor dimerization VEGF signal transduction in endothelial cells is initiated by binding and activating three related transmembrane receptor tyrosine kinases: VEGFR-1 (Flt-1), VEGFR-2 (Flk-1/KDR), and VEGFR-3 (Flt-4) (Devries et al., 1992; Joukov et al., 1996; Matthews et al., 1991; Terman et al., 1992) . All VEGFRs bear structural resemblance to the type III or PDGF/Fms/ Kit family of receptors that contain a split intracellular kinase domain. However, unlike the type III receptors that contain ®ve immunoglobulin-like (Ig) domains in their extracellular portion, VEGFRs contain seven. Multiple studies have shown that certain VEGFR Ig domains serve speci®c functions. Ligand binding appears to be mediated by Ig domains 1 through 3, ligand speci®city is directed by Ig domain 2, and receptor dimerization is optimized by Ig domain 4 (Barleon et al., 1997; Davis-Smyth et al., 1996; Fuh et al., 1998; Keyt et al., 1996; Weismann et al., 1997) .
Five VEGF-type ligands, VEGFs A, B, C, D, and PlGF exist which are encoded by separate genes. The three VEGFRs display distinct ligand anities for the various VEGFs. VEGFR-1 binds VEGFs A, B, and PlGF; VEGFR-2 binds VEGFs A, C, and D; and VEGFR-3 binds VEGFs C and D. In addition splice variants of VEGFs A and B have been identi®ed. These splice variants can be classi®ed by whether they are released as soluble ligand, or remain membrane bound. The dierent VEGF splice variants also display speci®city for binding distinct VEGFRs and coreceptor proteins including the neuropilins and heparin-sulfate proteoglycans. As the speci®cs of these interactions have recently been described in several excellent reviews Eriksson and Alitalo, 1999; Neufeld et al., 1999) , only the basics will be covered here. VEGFRs recognize VEGF ligands as disul®de linked dimers. As a member of the cystineknot growth factor superfamily (Sun and Davies, 1995) , VEGF dimerizes in an anti-parallel`side by side' orientation (Muller et al., 1997) . Crystal structure analysis aimed at identifying the binding motifs recognized by VEGFRs show that VEGF presents two receptor binding sites located near the poles of the dimer which straddle the interface between two receptor subunits (Muller et al., 1997; Weismann et al., 1997) .
The interaction across the interface of two receptor subunits triggers ligand-induced receptor dimerization thus initiating VEGF-induced signal transduction (Fuh et al., 1998) . Receptor dimerization is essential for both high anity binding to VEGF and receptor activation. An engineered VEGF mutant which is able to bind but not dimerize VEGFR subunits is completely inactive and antagonizes the activity of wild type VEGF (Fuh et al., 1998) . While VEGFRs are thought to signal mainly as homodimers, some evidence exists for heterodimerization of VEGFR-1 and -2 subunits upon binding to VEGFA (Kendall et al., 1996) .
Gene disruption experiments
Loss of a single allele of the endothelial cell mitogen, VEGFA, results in embryonic lethality at E11 Figure 1 Stages involved in vascular development. The processes involved in the generation of the vasculature are shown. Indicated below each stage are the molecules for which gene disruption experiments have suggested a requirement. Please refer to the text for detailed description of these stages and phenotypes. Adapted from (Carmeliet et al., 1996; Ferrara et al., 1996) . This result underscores the importance of VEGF receptor signaling in the developing vasculature. Mice homozygous for the VEGFR-1 null allele die between day 8.5 and 9.5 of embryogenesis due to disorganized blood vessels and misplaced endothelial cells (Fong et al., 1995) . Surprisingly, the expression of a VEGFR-1 lacking the tyrosine kinase domain is sucient for normal vessel formation and circumvention of lethality (Hiratsuka et al., 1998) . Mice homozygous null for VEGFR-2, die between E8.5 and E9.5 with a defect in endothelial and hematopoietic blood island formation (Shalaby et al., 1995) . Subsequent analysis, indicated that this is a primary defect which may be caused by the inability of VEGFR-2 cells to localize to the yolk sac from the primitive streak . More recently, it has been suggested that the hematopoietic cell defect can be partially overcome by speci®c in vitro culture conditions, while the defect in endothelial cell dierentiation cannot (Hidaka et al., 1999) . These results indicate an absolute requirement for VEGFR-2 in endothelial cell dierentiation, but a conditional role for VEGFR-2 in hematopoietic cell dierentiation. Finally, VEGFR-3 embryos experience cardiovascular failure between E10 and E12 from defects in remodeling the primary vessel networks into larger blood vessels .
Intracellular signaling
Upon stimulation by ligand, transmembrane receptor tyrosine kinases appear to share a common signaling paradigm. Ligand binding induces receptor dimerization, which results in activation of intrinsic tyrosine kinase activity. The activated receptor undergoes autophosphorylation which promotes receptor association with, and activation of, intracellular signal relay proteins. Most of these proteins contain modules such as SH2 and PTB domains, that promote binding to phosphorylated tyrosine residues on the activated receptor (Cantley et al., 1991; Pawson and Scott, 1997; Ullrich and Schlessinger, 1990) . For a summary of these interactions, please see Table 1 . Some of these also contain SH3 domains which mediate interactions with proteins containing proline rich motifs (Cantley et al., 1991; Pawson and Scott, 1997) . These receptorassociated proteins can be placed into several categories: (1) enzymatic proteins such as phosphatidyl inositol 3-kinase (PI3K), phospholipase Cg (PLCg), Src family kinases, and the tyrosine phosphatase, SHP-2, (2) non-enzymatic adaptor proteins such as Grb-2, Shc, and Nck, (3) cytoskeletal proteins such as tensin and (4) transcription factors such as the STATs.
VEGFR autophosphorylation Over the past several years, substantial progress has been made on de®ning the signaling events that carry out the cellular function of VEGFRs. Most of this eort has concentrated on signal transduction by VEGFRs 1 and 2 following activation by VEGFA (from here on referred to as VEGF). VEGFRs 1 and 2 are structurally very similar, and in principle follow the signaling protocol brie¯y described above. Both receptors autophosphorylate in response to VEGF binding (Waltenberger et al., 1994) . This event appears to be required for VEGF-induced proliferation of endothelial cells since this function can be inhibited by pretreatment with the tyrosine kinase inhibitor genistein (Guo et al., 1995) . Furthermore, autophosphorylation leads to the binding and activation of a number of signal transduction proteins in a cell type speci®c manner. Known signaling proteins which have been reported to become tyrosine phosphorylated in response to VEGF include: PLCg, the GTPase activating protein of Ras (RasGAP), PI3K, Shc, SHP-1, SHP-2, the focal adhesion kinase (FAK), and the FAK related kinase, Pyk2 (Abedi and Zachary, 1997; Guo et al., 1995; Kroll and Waltenberger, 1997; Mukhopadhyay et al., 1998; Seetharam et al., 1995; Takahashi and Shibuya, 1997) .
VEGFRs 1 and 2 transmit distinct signals Despite some apparent similarities, several lines of evidence indicate that the signaling capacities of these two receptors are functionally distinct. The ®rst indication that the two VEGFRs have dierent signaling capacities came from studies which showed that while VEGFR-1 has a higher anity for VEGFA (Kd=10 ± 100 pM) compared to that of VEGFR-2 (Kd=400 ± 800 pM). In contrast, VEGF-induced autophosphorylation of VEGFR-1, at least in certain cell types, is greatly reduced compared to levels observed for VEGFR-2 (Waltenberger et al., 1994) . Interestingly, activation of VEGFR-1 but not 2 induced tyrosine phosphorylation of two cytoplasmic tyrosine kinases of the Src family, Fyn and Yes (Waltenberger et al., (Seetharam et al., 1995; Takahashi and Shibuya, 1997; Waltenberger et al., 1994) . Moreover, when the VEGFR-1 speci®c ligand, PlGF was compared to VEGF in terms of the ability to stimulate mitogenesis in endothelial cells, PlGF was found to be much less active (Hauser and Weich, 1993) . In complement to the above experiments, endothelial cell proliferation in an in vivo model of tumor angiogenesis was blocked upon introduction of a dominant negative version of VEGFR-2 (Millauer et al., 1994) . The ability of VEGFR-2 but not VEGFR-1 to promote mitogenesis in response to VEGF correlates with the exclusive ability of VEGFR-2 to turn on MAP kinase (MAPK) (Kroll and Waltenberger, 1997) . Other, non-mitogenic functions induced by VEGF also appear to be directed primarily by VEGFR-2. In porcine aortic endothelial (PAE) cells which lack endogenous expression of VEGFRs, only expression of VEGFR-2 results in the ability to respond to VEGF in assays for actin cytoskeleton modi®cation and chemotaxis (Waltenberger et al., 1994) . Finally, stimulation of primary endothelial cells expressing both VEGFRs with a VEGF mutant that selectively activates VEGFR-2 results in high levels of survival activity under starvation conditions, whereas VEGFR-1 speci®c ligands fail to do so (Gerber et al., 1998) . Taken together, these studies suggest that VEGFR-2 is the primary positive mediator of VEGF function in endothelial cells. This is consistent with the observation that endothelial cells and all major blood vessels largely fail to develop in embryos lacking either VEGF or VEGFR-2 (Carmeliet et al., 1996; Ferrara et al., 1996; Shalaby et al., 1995) .
Substantial evidence indicates that VEGFR-1 may act to negatively regulate VEGFR-2 signaling in endothelial cells. In contrast to the VEGFR-2 knock out phenotype, embryos lacking VEGFR-1 contain blood vessels which are abnormally organized apparently due to an excess of endothelial cells (Fong et al., 1995) . Evidence which suggests that VEGFR-1 may transmit signals which negatively regulate cell proliferation, comes from the observation that when coexpressed with STAT5, only VEGFR-1 substantially increases expression of the cell cycle inhibitor p21 (Korpelainen et al., 1999) . However, VEGFR-1 may act primarily as a ligand binding molecule controlling the amount of VEGF seen by VEGFR-2. Dramatic evidence that this is in fact the case comes from the observation that a VEGFR-1 lacking its tyrosine kinase domain is sucient for embryonic development and angiogenesis in mice (Hiratsuka et al., 1998) . Thus, strong evidence indicates that distinct mechanisms of signal transduction are likely to account for the dierent physiological functions demonstrated by targeted deletion of each receptor.
Targeted deletion of the intracellular domain of VEGFR-1 indicates that VEGFR-1-mediated signal transduction is dispensable for endothelial cell function, and prompts the question of why this receptor contains an intracellular signaling domain (Hiratsuka et al., 1998) . Answers to this question come from several studies which indicate that VEGFR-1 signaling is required for optimal monocyte and trophoblast function. Both PlGF and VEGF stimulate tissue factor induction and chemotaxis in monocytes which express VEGFR-1 exclusively (Clauss et al., 1996) . In complement to this study, macrophages derived from mice expressing the intracellular domain deletion mutant of VEGFR-1, displayed markedly decreased levels of migration toward VEGF and PlGF compared to wild-type controls (Hiratsuka et al., 1998) . The signaling mechanism that underlies VEGFR-1-mediated chemotaxis has yet to be elucidated. However, studies utilizing the two hybrid system in yeast, or overexpression of VEGFR-1 in insect cells have identi®ed PLCg, PI3K, and SHP-2 as potential downstream eectors of VEGFR-1 (Cunningham et al., 1995; Igarashi et al., 1998; Sawano et al., 1997) . All three of these enzymes have been reported to promote chemotaxis driven by the PDGFbR (Kundra et al., 1994; Qi et al., 1999) . While VEGFR-1 signaling promotes migration of monocytes, a recent study indicates that it is also critical for promoting PlGFstimulated trophoblast survival under serum starvation conditions (Desai et al., 1999) . The capacity of PlGF to act as a survival factor correlates with its ability to induce activation of the stress-activated protein kinase (SAPK) pathways (Desai et al., 1999) . This result suggests that activation of SAPK by VEGFR-1 may promote vascularization of the placenta during embryogenesis.
Eectors of VEGFR-2 signal transduction Ras/MAP kinase Of the wide array of signaling proteins activated in response to VEGF, members of the MAPK family appear to play the most prominent roles in regulating VEGF-induced functions required for vascular development, such as, mitogenesis, protection from apoptosis, and chemotaxis. Although it is now known that several intracellular routes lead to the activation of dierent MAPK family members, the most well characterized downstream of receptor tyrosine kinase activation is the Ras/Raf/Mek/p42/44 MAPK pathway (from here on referred to as MAPK unless otherwise noted). In brief, receptor autophosphorylation leads to binding of the SH2/SH3 domaincontaining adaptor molecule Grb2 either directly, or via interaction with other receptor-associated proteins such as Shc, Nck, or SHP-2. Recruitment of Grb2 leads to translocation of the guanine nucleotide exchange factor Sos to the plasma membrane where Sos converts inactive GDP bound Ras to active GTPbound Ras. GTP-bound Ras promotes the translocation of the serine/threonine kinase Raf to the plasma membrane where Raf is activated leading to phosphorylation and activation of the dual speci®city kinase MEK-1. MEK-1 in turn phosphorylates and activates MAPK (reviewed in Pawson and Scott, 1997) . Ras is turned o by cleavage of GTP into GDP and free phosphate. Since Ras contains very low intrinsic GTPase activity, the GTPase activating protein, RasGAP, is required to enhance the conversion of GTP-bound Ras back to its inactive GDP-bound state. RasGAP is therefore thought to act primarily as a negative regulator of Ras activity (reviewed in Bollag and McCormick, 1991) .
Multiple studies performed on a variety of endothelial and ®broblast cell lines, as well as on intact mouse mesentery vascular endothelium, have demonstrated that MAPK is phosphorylated and activated in response to VEGF, presumably via activation of VEGFR-2 (D' Angelo et al., 1995; Gupta et al., 1999; Kroll and Waltenberger, 1997; Mukhopadhyay et al., 1998; Rousseau et al., 1997; Takahashi and Shibuya, 1997; Yu and Sato, 1999) . Several pathways appear to link VEGFR-2 activation to the Ras/MAPK cascade. VEGFR-2 can bind to Grb2 directly, or indirectly via tyrosine phosphorylated Shc, Nck, or SHP-2 (Kroll and Waltenberger, 1997) . VEGFR-2-mediated activation of Ras is likely to be modulated by RasGAP, as VEGF stimulates both tyrosine phosphorylation of RasGAP and its association with VEGFR-2 (D' Angelo et al., 1999; Guo et al., 1995) . SHP-2, therefore, may not only promote Ras/ MAPK activation via its capacity to bind GRB2, but may also enhance this signaling event by dephosphorylating the RasGAP binding site on VEGFR-2. SHP-2 has been shown to dephosphorylate the RasGAP binding site on the PDGFbR, and the drosophila homologue of SHP-2, csw, has recently been shown to dephosphorylate the RasGAP binding site on the Torso receptor tyrosine kinase (Cleghon et al., 1998; DeMali et al., 1999; Klinghoer and Kazlauskas, 1995) . VEGF also induces tyrosine phosphorylation, and presumably the activation of FAK and Pyk2, both of which have been shown to promote the activation of MAPK (Lev et al., 1995; Schlaepfer et al., 1994) . VEGF-induced activation of PI3K may also enhance activation of the Ras/MAPK cascade. Inhibition of PI3K by either addition of a speci®c inhibitor, wortmannin, or by expression of a dominant negative version of the p85 subunit of PI3K, has been shown to partially inhibit VEGF-induced activation of MAPK and endothelial cell proliferation, although this appears to be cell type speci®c (Thakker et al., 1999; Yu and Sato, 1999) .
The importance of Ras/MAPK to VEGFR function in vitro has been indicated by multiple studies. Inhibition of the Ras/MAPK cascade with either a speci®c inhibitor of the MAPK activating protein MEK-1, or an anti-angiogenic molecule, the 16 kDa N-terminal fragment of prolactin, severely impairs endothelial cell proliferation as well as survivability under pro-apoptotic conditions (D'Angelo et al., 1995; Gupta et al., 1999; Rousseau et al., 1997; Yu and Sato, 1999) . The biological relevance of the Ras/MAPK cascade to vasculogenesis and angiogenesis is underscored by the demonstration that targeted deletion of genes encoding proteins involved in either relay or regulation of this signaling pathway, including Sos1, Braf, Mek1, SHP-2, or RasGAP, leads to vascular defects during embryogenesis as will be discussed below (Giroux et al., 1999; Henkemeyer et al., 1995 P38 MAP Kinase While p42/44 MAPK promotes endothelial cell proliferation, a related molecule p38 MAPK, negatively regulates this process, as inhibition of p38 enhances VEGF-stimulated proliferation. Although the exact mechanism of this regulation of the cell cycle is unclear, inhibition of p38 has been shown to correlate with decreased expression of the cdk inhibitor p27Kip1 and hyperphosphorylation of the Rb tumor suppressor protein (Yu and Sato, 1999) . In contrast to its role as a negative regulator of proliferation, p38 positively modulates VEGF-induced actin reorganization and cell migration via activation of MAP kinase activated protein kinase-2/3 and subsequent phosphorylation of the F-actin polymerization modulator, heat shock protein 27 (HSP-27) (Rousseau et al., 1997) . Interestingly, a similar role for p38 has recently been demonstrated downstream of PDGFR activation (Matsumoto et al., 1999) .
PLCg/PKC Activation of the PLCg/PKC pathway may also contribute to VEGF-induced endothelial cell proliferation. When activated, PLCg cleaves phosphatidyl inositol 4,5 bisphosphate into 2 s messenger molecules: inositol triphosphate (IP3) which triggers an increase in cytosolic Ca 2+ levels, and diacylglycerol (DAG) which activates PKC family members (Berridge, 1987; Nishizuka, 1984) . In endothelial cells expressing endogenous VEGFRs and in NIH3T3 ®broblasts overexpressing VEGFR-2, PLCg has been shown to associate with, and act as a substrate for the activated VEGFR-2 (D' Angelo et al., 1995; Guo et al., 1995; Takahashi and Shibuya, 1997; Waltenberger et al., 1994) . Importantly, stimulation of endothelial cells with VEGF leads to an increase in PLCg enzymatic activity (Xia et al., 1996) . This is consistent with reports that tyrosine phosphorylation promotes activation of PLCg and that VEGF induces an increase in intracellular Ca 2+ levels (Brock et al., 1991) . Furthermore, VEGF induces activation of PKC a and b2 isoforms, and in some endothelial cell culture systems, proliferation stimulated by VEGF can be blocked by speci®cally inhibiting PKC-b2 (Xia et al., 1996) . Finally, the relevance of PKC activation to VEGF function in vivo was established by demonstrating that VEGF-induced angiogenesis on chick chorioallantoic membrane is blocked by the application of a speci®c inhibitor to PKCs (Friedlander et al., 1995) .
Angiopoietin/TIE receptor signal transduction

Ligand binding
Other endothelial cell speci®c receptor tyrosine kinases critical to vascularization are the members of the Tie family, Tie1 and Tie2. Tie receptor function, at least in part, is regulated by ligand binding to the extracellular domain of the receptor. While the intracellular structure of Tie receptors is similar to that of VEGFRs and PDGFR family members, the extracellular portion of Tie receptors is unique. This portion consists of three N-terminal EGF-like motifs anked by Ig-like domains, followed by three ®bronectin type three domains (Partanen et al., 1992; Ziegler et al., 1993) . Four Tie receptor ligands, angiopoietins (Ang1 ± 4) have been cloned to date. All angiopoietins are structurally similar, consisting of an N-terminal region lacking homology to any known structures, an a-helical rich coiled-coil domain similar to structures found in proteins which induce multimerization, and a c-terminal ®brinogen-like region which has been suggested to contain the receptor binding portion of these ligands Maisonpierre et al., 1997; Valenzuela et al., 1999) . All angiopoietins identi®ed thus far bind Tie2 exclusively Maisonpierre et al., 1997; Valenzuela et al., 1999) . Tie2 activation is precisely regulated by the opposing actions of agonistic and antagonistic angiopoietins. This is best characterized in studies on the eect of Ang1 (agonist) and Ang2 (antagonist) on Tie2 activity and vascular development (Maisonpierre et al., 1997) . Targeted deletion of Ang1 and transgenic over-expression of Ang2 nearly recapitulate the phenotype of Tie2 disrupted mice con®rming the roles of these two ligands as agonist and antagonist of Tie2 in vivo (Maisonpierre et al., 1997; Suri et al., 1996) . Conversely, transgenic overexpression of Ang1 results in increased vascularization (Suri et al., 1998) . Despite several extensive eorts, attempts to identify Tie1 ligand(s) have not succeeded. This suggests the possibility that Tie1 is unable to bind ligand in an independent manner, but instead acts as a co-receptor to optimize the ligand binding capacity of another endothelial cell surface receptor such as Tie2. Whether angiopoietin binding induces homo-or heterodimerization of Tie receptor subunits has yet to be determined.
Gene disruption experiments
Both Tie1 and Tie2 receptors have been disrupted in the mouse, and endothelial cell survival is aected to dierent degrees by loss of each receptor. Mice lacking Tie1 die before E15 or at P1 (depending on the genetic background) Sato et al., 1995) . The cause of death is apparently loss of microvascular integrity resulting in hemorrhaging. The major vessels and extra-embryonic vasculature appear normal. The importance of Tie1 during the maturation stage of vascular development is further supported by chimeric analysis which indicated a primary endothelial cell defect later in angiogenesis, possibly eecting proliferation (Partanen et al., 1996) . Tie2 null embryos, in contrast, die at E9.5, with loss of vascular integrity and reduction in endothelial cell numbers (Dumont et al., 1994; Sato et al., 1995) . Subsequently, Tie2 was also shown to be critical for de®nitive hematopoiesis and induced hematopoietic cell adhesion to extracellular matrix (Takakura et al., 1998 ) whereas Tie1 appears to be dispensable for hematopoiesis (Partanen et al., 1996; Rodewald and Sato, 1996) . Analyses such as these indicated the importance of Tie receptors in angiogenesis and sparked inquiry into the signaling pathways downstream of these receptors.
Intracellular signaling/cellular function
Targeted deletion of Tie1 and Tie2 indicate that at least some of the cellular functions mediated by Tie2 are distinct from those directed by Tie1, as well as those regulated by the VEGF receptors. While the lack of an identi®ed ligand for Tie1 has impeded analysis of the cellular function of this receptor, the recent cloning of Tie2 ligands has shed some light on Tie2 function. Similar to other transmembrane tyrosine kinases, Tie2 undergoes autophosphorylation in response to binding its agonist, Ang1 . Tight regulation of the autophosphorylation state of Tie2 is crucial to normal development and maintenance of the vasculature. A Tie2 mutation, which results in ligand-independent and enhanced autophosphorylation, causes hereditary venous malformations (Vikkula et al., 1996) . Conversely, transgenic mice that overexpress a kinase-inactive form of Tie2 die in utero and display similar defects in the integrity of their endothelium as Tie2 null mice (Dumont et al., 1994) . Interestingly, unlike activation of VEGFR-2, activation of Tie2 does not promote proliferation, tubule formation, or survival of endothelial cells in culture Witzenbichler et al., 1998) . Instead, Ang-1 has been shown to induce chemotactic migration as well as angiogenic sprouting of endothelial cells, events which require modi®cations of the actin cytoskeleton as well as coordinated interactions with extracellular matrix proteins (Koblizek et al., 1998; Witzenbichler et al., 1998) . The in vitro functions of Tie2 are consistent with the abnormal appearance of endothelial cells in Ang1 null embryos. These cells do not undergo proper morphologic changes such as spreading and¯attening, but instead are aberrantly rounded and are poorly associated with the underlying matrix and periendothelial cells (Suri et al., 1996) . Thus, while activation of VEGFR-2 is required to initiate vasculogenesis and angiogenesis by promoting endothelial cell proliferation and survival, activation of Tie2 modulates cell ± cell and cell ± matrix interactions, events required for vascular remodeling and maturation.
Although the natural ligands for Tie2 have only recently been discovered, initial insights regarding signaling pathways downstream of Tie2 activation have been elicited. Several of the signaling molecules that bind Tie2 provide possible links to modi®cation of the actin cytoskeleton. First, Tie2 has recently been shown to bind and activate PI3K (Kontos et al., 1998) , potentially linking Tie2 activation to activation of the Rac GTPase (Hawkins et al., 1995) , a molecule intricately involved in regulating the actin cytoskeleton (Nobes and Hall, 1995) . Second, a novel adaptor molecule named Dok-R, has recently been identi®ed as a substrate for tyrosine phosphorylation by Tie2 (Jones and Dumont, 1998). Dok-R contains an Nterminal plextrin homology domain, followed by a PTB domain, and ®nally a C-terminal tail region that contains SH3 binding motifs. When tyrosine phosphorylated, Dok-R interacts with the adaptor protein Nck which in turn associates with several molecules involved in growth factor-regulated actin assembly. These include the Wiskott-Aldrich syndrome protein (WASP), PRK2, a kinase which is a potential eector of Rho, and WIP, a protein which binds to pro®lin (Anton et al., 1998; Jones and Dumont, 1998; Quilliam et al., 1996; Rivero-Lezcano et al., 1995) . Furthermore, tyrosine phosphorylated Dok-R associates with RasGAP suggesting that Tie2 function is mediated at least in part by regulating the Ras cascade (Jones and Dumont, 1998). Dok-R also associates with the Crk adaptor protein in a constitutive manner which potentially links Tie2 to activation of Ras, the ras-related protein Rap1, and the focal adhesion kinase (FAK) Hanks and Polte, 1997; Jones and Dumont, 1998; Tanaka et al., 1993) . Consistent with the idea that signaling through Ras is important for Tie2 function, two other molecules involved in regulating Ras signaling, SHP-2 and Grb2, have been shown to associate directly with Tie2 in a phosphotyrosinedependent manner by two-hybrid analysis (Huang et al., 1995) . The fact that disruption of several molecules involved in the Ras cascade, including Braf and RasGAP, result in endothelial cell abnormalities which appear to be similar to those seen in Tie2 and Ang1 knock-out mice further promotes this possibility (Henkemeyer et al., 1995; Wojnowski et al., 1997) . Finally, Tie2 may transmit signals directly to the nucleus via activation of STATs 3 and 5. Intriguingly, the mutant of Tie2 which causes venous malformations, displays an elevated capacity to activate STATs 3 and 5, and unlike wild type Tie2, also activates STAT1 (Korpelainen et al., 1999) . Many of the autophosphorylation sites within Tie2 have now been identi®ed, and appear to bind to the aforementioned SH2 domain-containing signaling molecules with a reasonable degree of speci®city (Huang et al., 1995; Kontos et al., 1998) . Therefore, targeted mutations of these sites in the mouse via homologous recombination in ES cells may provide valuable insights as to how each of the Tie2-associated signal relay proteins contributes to the physiological function of this receptor.
Eph receptor signal transduction
Ligand binding, receptor dimerization, and cellular function
The Eph receptor family is a third tyrosine kinase group shown to regulate the development and function of blood vessels, but unlike the Tie and VEGF receptors which are expressed exclusively on endothelial cells, the Eph receptors are expressed more broadly. Initially, these receptors were identi®ed and characterized by their expression in the nervous system, where they participate in axon guidance and neural patterning (Krull et al., 1997; Smith et al., 1997; Wang and Anderson, 1997) . More recently Eph receptors and ligands have been reported in many dierent tissues and induce cellular responses, such as cell adhesion, morphogenesis, capillary sprouting, and chemoattraction (Bohme et al., 1996; Mellitzer et al., 1999; George et al., 1998; Adams et al., 1999; Panley et al., 1995b) . The Eph receptors' mode of action is not that of inducing mitogenesis like many other RTKs, but instead they seem to control cell localization. Thus far there are 14 vertebrate receptors and eight ligands (reviewed by Flanagan and Vanderhaeghen, 1998) .
Unlike many ligands for receptor tyrosine kinases, the Eph ligands (ephrins) are membrane bound and are divided into two groups which share between 23 and 56% identity at the amino acid level (Gale et al., 1996a) . The A group is GPI linked while the B group contains a single transmembrane domain and a short, highly conserved cytoplasmic tail. The fact that the ligands are cell bound leads to three interesting features. First, the expression on the cell surface is absolutely required because soluble ligands do not activate the receptors as eciently as membrane bound or arti®cially aggregated ligands (Davis et al., 1994) . This is presumably because the receptors need to be clustered in order to achieve activation. Membrane or matrix bound ligands are not uncommon for other RTK family members, but this cell bound requirement for activation of the receptors is unique to the ephrins. Second, ephrin signaling can only work over short distances, i.e. on a cell to cell basis. Finally, membrane bound ligands allow for the possibility of bi-directional signaling.
Like the ligands, the Eph receptors form two closely related subgroups, A and B, which are based on structural homology and ligand speci®city. The A receptors only bind GPI-linked ligands, and similarly the B receptors only bind the transmembrane ephrins. Binding of ligands across subgroups is rare while ligand binding within a subgroup can be promiscuous (Brambilla et al., 1995; Gale et al., 1996b) . The receptors contain three distinct extracellular motifs; a globular domain, a cysteine-rich region, and two ®bronectin type III repeats. It appears that the globular domains of the receptors are important for ligand binding (Himanen et al., 1998; Labrador et al., 1997) , while the other domains may play a role in receptor dimerization or stabilization (Lackmann et al., 1998) . The cytoplasmic region consists of a single tyrosine kinase domain, several consensus binding sites for SH2-containing proteins, and unique domains including a PDZ binding module (Torres et al., 1998 ) and a sterile alpha motif, SAM. The SAM domain may function to enhance oligomerization (Thanos et al., 1999) or to recruit signaling partners through heteromeric SAM domain interactions (Stapleton et al., 1999) .
Gene disruption experiments
One of the ®rst Eph family members to be disrupted, EphA2, had no discernible phenotype, indicating some redundancy of Eph receptor signaling . However, not all ephrin signals are redundant. Ephrin B2 null mice have severe defects in vascular remodeling, a phenotype very similar to that of Tie2 de®cient mice. Ephrin B2 is expressed exclusively in arterial endothelial cells, and a receptor for this ephrin, EphB4 is expressed only on venous vessels. The ephrin B2 mutant embryos exhibited defects in both arteries and veins supporting the model of bi-directional signaling between Eph receptors and their ligands (Wang et al., 1998) . It is unlikely that EphB4 is the only Eph receptor involved in vascular development. Indeed, vascular defects similar to the ephrinB2 knockout were observed (with 30% penetrance) in EphB2/EphB3 double homozygous null embryos (Adams et al., 1999) . The aected double mutant embryos often had abnormal vascular remodeling. These results implicate a complex pattern of signals involving multiple Eph receptors and ephrins in the establishment of the vasculature during embryogenesis.
Intracellular signaling
The study of signaling molecules downstream of the Eph receptors has been lagging behind that of other RTKs. One would assume by its homology to other RTKs that binding of ligand would modulate kinase activity and consequential activation of intracellular targets. However, for many years these events could only be assumed because no ligands had been identi®ed for the Eph receptors. Therefore, there was no ecient means of inducing receptor activation. Furthermore, few proteins associate with the Eph receptors upon stimulation in ®broblast cells. A ®nal hindrance has been that the Eph receptors are involved in path®nding and not proliferation, and less is known about the signaling involved with this biological function, though presumably the components controlling cytoskeletal rearrangements would be important. To circumvent these issues, some investigators have used yeast 2-hybrid screens with subsequent supporting information of in vivo relevance. In 1994, ligands were identi®ed for the Eph receptors and several groups noted the requirement for clustering (Bartley et al., 1994; Beckmann et al., 1994; Davis et al., 1994; Shao et al., 1994 Shao et al., , 1995 . These results paved the way for studying the eector molecules of the Eph receptors upon activation. Given the size of the Eph receptor family and the limited information of downstream signaling, for the purpose of this review we will discuss all of the potential signals identi®ed upon receptor (and ligand) stimulation, with reference to each receptor responsible for that signal.
Enzymatic SH2 domain-containing eectors of Eph function
The primary function of Eph receptor signaling in vascular development appears to be to regulate cell positioning. To do so, Eph receptors must respond to extracellular cues and rearrange the actin cytoskeleton. Initially, it was found that the p85 regulatory subunit of PI3K associated with the EphA2 cytoplasmic domain in a yeast 2-hybrid screen. The in vivo relevance of this association was demonstrated in VSMC where EphA2 stimulation lead to an eightfold increase in PI3K activity . Given that downstream of the PDGFb receptor, PI3K has been shown to promote chemotaxis and cytoskeletal rearrangements via its ability to activate Rac, a small GTPase which regulates the formation of lamellipodia, PI3K is a strong candidate as a link between Eph receptor activation and modi®cation of the cytoskeleton.
Another family of enzymes which modulate Eph receptor mediated changes in the cytoskeleton is the src family kinases (SFK). SFK are cytoplasmic tyrosine kinases that regulate many cellular functions including mitogenesis, organization of the cytoskeleton and cell scattering. The juxtamembrane domains of several Eph receptors contain consensus binding sites for SFK, and these sites can become autophosphorylated (Ellis et al., 1996; Zisch et al., 1998) . EphB2 binds Src, while EphA4 and EphB3 have been shown to bind Fyn (Ellis et al., 1996; Hock et al., 1998a; Zisch et al., 1998) . Therefore SFK signaling appears to be a common pathway used by Eph receptors. SFK may exert their function by phosphorylating and activating various cytoskeletal proteins including FAK, paxillin, and tensin (among others). These proteins may then in turn be involved in cytoskeleton dynamics which is involved in cell motility and guidance (Brown and Cooper, 1996; Lowell and Soriano, 1996; Thomas and Brugge, 1997) .
A third enzyme which potentially regulates Eph receptor cytoskeletal modi®cation is RasGAP. The juxtamembrane domains of EphB2 and EphB3 have also been shown to associate with RasGAP (Hock et al., 1998a; Holland et al., 1997) . As discussed above, RasGAP is a negative regulator of Ras signaling and thus has the capacity to aect the cytoskeleton by regulating this pathway. However, RasGAP may also regulate the cytoskeleton by its constitutive association with p190 RhoGAP (Settleman et al., 1992) . RhoGAP is a negative regulator of Rho, which along with Cdc42 appears to be important for cytoskeletal rearrangements. This cascade again ties Eph signaling to regulators of the actin cytoskeleton. Previous evidence that RasGAP binding can negatively regulate actin cytoskeletal rearrangements come from studies of the PDGFRb. Cells expressing mutant PDGFRb receptors which can no longer bind RasGAP, display enhanced ability to migrate toward PDGF (Kundra et al., 1994) . Thus it is possible that RasGAP/RhoGAP is a common negative regulator of RTK-mediated cytoskeletal rearrangements.
SH2 domain-containing adaptor molecules as eectors of
Eph signaling A multitude of adaptor molecules has been shown to associate with Eph receptors and may provide potential links to the actin cytoskeleton. Adaptor molecules are de®ned by their ability to bind multiple proteins without possessing catalytic activity of their own. The ®rst Eph adaptor molecule described was the novel protein, SLAP, which was identi®ed in a yeast 2-hybrid screen with EphA2 (Pandey et al., 1995a) . SLAP (Src-like adaptor protein) has an SH2 and SH3 domain with substantial homology to Src, but it lacks the tyrosine kinase catalytic activity. Thus far SLAP has been proposed to be a negative regulator of PDGFRb signaling (Roche et al., 1998) . A second set of adaptors shown to bind EphB1 in endothelial cells are Grb2 and Grb10 (Stein et al., 1996) . The Grbs are SH2 domain containing proteins that function downstream of many other RTKs. Grb2 is involved in both the RAS pathway and cytoskeletal rearrangements. The role of Grb2 in actin dynamics has been shown to be upstream of N-WASP, which regulates the cortical actin cytoskeleton (Miki et al., 1996) . Grb2 can also be linked to control of the cytoskeleton by its association with Sos, an activator of Ras and Rac (Nimnual et al., 1998) . Although at present the role of Grb10 has not been thoroughly characterized it may act in a similar fashion to Grb2. Yet another adaptor, Nck, has been implicated in Eph signaling by two separate reports. EphB2 binds Nck (and RasGAP) possibly via p62 dok (Holland et al., 1997) . P62 dok has scaolding and signaling properties similar to Dok-R discussed earlier. Another group has implicated direct binding of Nck to the EphB1 receptor and demonstrated Nck-dependent c-jun n-terminal kinase (JNK) activity upon receptor stimulation (Stein et al., 1998) .
Distinct pathways activated The intracellular signaling molecules listed above can be tied to multiple RTKs as indicated previously for VEGFR and Tie receptor signaling. In fact, it is often dicult to determine if the immediate responses are distinct at all. This is emphasized by the recent analysis of ®broblast growth factor receptor1 (FGFR1) and PDGFRb immediate early gene transcription, where very few qualitative dierences in gene induction were observed between the receptors (Fambrough et al., 1999) . However, the Eph receptors signal by some unique pathways, because they possess two protein module domains not described in other RTKs. The SAM domain is one of these motifs, although further analysis is required to determine if it has a role in signaling in the Eph receptors. The other domain is the PDZ (PSD-95, Dlg, ZO-1) binding motif. This motif is a short peptide sequence usually at the C termini of proteins which is recognized by PDZ domain containing proteins. These proteins form a large class of signaling and cytoskeletal proteins which include membrane associated guanylate kinases, protein tyrosine phosphatases, serine/threonine kinases and many others (reviewed by Fanning and Anderson, 1998; Ponting et al., 1997) . PDZ domain family members are believed to act as scaolds, especially when localized to specialized membranous sites. Recent evidence indicates that both ephrins and their receptors have the capacity to signal through PDZ domain containing proteins. Multiple reports suggest that a range of these proteins can associate with the ephrins and their receptors, including FAP-1, syntenin, GRIP, GRIP2, AF6, PICK1 and PHIP (Bruckner et al., 1999; Hock et al., 1998b; Torres et al., 1998) . Several possible reasons exist for this association with ephrins and the Eph receptors. PDZ domain-containing proteins may simply enhance the clustering that is required for ecient activation. In support of this idea, one group has shown that PICK-1 becomes phosphorylated following stimulation of EphB2 and that the association of PICK-1 leads to EphB2 and ephrinB1 clustering at the cell surface (Torres et al., 1998) . A second function may be to act as a scaold for signaling complexes. Indeed, it has been shown that full length AF6, capable of binding Ras in vitro (Kuriyama et al., 1996) , only bound EphB3 when its kinase domain was intact (Hock et al., 1998b) . This result suggests an activation-regulated interaction of EphB3 with AF6, providing another level of regulation for signaling. Because several Eph receptors also bind RasGAP, it is interesting to speculate that AF6 may bring RasGAP in proximity to Ras thereby modulating its signal. Finally, as discussed below, PDZ domain proteins may potentiate ephrin signaling.
Ephrin intracellular signaling As mentioned previously, two classes of ephrins exist, a GPI class and a transmembrane class. In T cells, there is precedence for GPI-linked proteins transducing a signal internally (Brown, 1993) , but thus far there is no evidence for this type of signal in the ephrin system. Therefore, we will focus on the B ligands, which do contain a cytoplasmic tail. The cytoplasmic domain (83 ± 89 amino acids) of the three B ligands is the most highly conserved region over the entire length of the protein (Gale et al., 1996a) . This region contains both a PDZ domain binding motif and potential tyrosine phosphorylation sites. So how does the tail transduce an intracellular signal? Two groups have shown that ephrinB1 and ephrinB2 become phosphorylated on tyrosine after stimulation by cell-bound or soluble clustered EphB2 (Adams et al., 1999; Bruckner et al., 1997; Holland et al., 1996) . This phosphorylation can be mediated by several tyrosine kinases in vitro and in vivo. The kinases studied include v-src, Tie-2, and PDGFRb. In the case of PDGFRb, the ephrin phosphorylation could be observed in the absence of Eph receptor ligation but in the presence of PDGFRb activation. This provides the possibility for receptor crosstalk. Recently, it has been demonstrated that the eprhinB1 PDZ binding motif recruits GRIP and GRIP2 into membrane rafts, and that there is a serine/threonine kinase activity associated with this complex (Bruckner et al., 1999) . This data provides a second mechanism for ephrin signaling via PDZ domain proteins. Many signaling molecules are reportedly enriched in rafts; these include SFK, Ras and trimeric G proteins. (Simons and Ikonen, 1997) . With the PDZ domain proteins acting as scaolds, it is not dicult to envision ephrins transducing a signal inwardly. Support for intracellular signalling was observed in the mouse when disruption of full length EphB2, but not kinase de®cient EphB2, resulted in axonal defects, and the aected neurons are those bearing the ligand, not the receptor . Although this eect does not have to be caused by a loss of ephrin signal, with the supporting data listed above it certainly opens up possibilities for further research in bidirectional signaling.
PDGF receptors
Ligand binding and receptor dimerization
As mentioned in the introduction, endothelial cells are not the only cells of the vasculature. VSMC are a primary component of the vasculature in regards to both its structure and function. Evidence from PDGF receptor and PDGF ligand null mice, as well as studies on PDGF in athlerosclerosis and wounding, implicate PDGF signaling as a key regulator in smooth muscle cell (SMC) development and function (LeveÂ en et al., 1994; Lindahl et al., 1997b; Ross et al., 1990; Soriano, 1994) . The PDGF receptor family consists of two proteins, a and b, which homo and heterodimerize, and two ligands, A and B, which also homo and heterodimerize. The PDGFRb can only bind the B ligand with high anity, whereas the PDGFRa can bind all possible ligands (Heldin et al., 1998) .
Gene disruption experiments
PDGFRb Despite its widespread expression, generation of mice homozygous null for the PDGFRb results in a fairly speci®c phenotype; the integrity of the microvasculature is compromised (Soriano, 1994) . Mutant animals have extensive hemorrhaging, edema, and lack kidney mesangial cells. A strikingly similar phenotype is observed with the ligand knockout, PDGFB (Leveen et al., 1994; Lindahl et al., 1997a) even though the B ligand also activates the PDGFRa.
Further, analysis of these mice suggests that the B ligand secreted by the vascular endothelial cells control the formation of the VSMC layer in multiple tissue types including, brain, kidney, and limb (Hellstrom et al., 1999; Lindahl et al., 1997a Lindahl et al., , 1998 . The development of the VSMC layer occurs by both recruitment of adjacent mesenchymal cells and migration of existing cells along the newly formed sprout. It is somewhat puzzling that while the b receptor is expressed in all VSMC, no striking phenotype is observed in the large vessels. This mystery was addressed by generating chimeric mice and comparing the number of mutant cells present in the large and small vessels to the number of wild type cells present in the same regions. PDGFRb 7/7 cells were dramatically selected against in the VSMC of several organs, including the aorta, kidney, arterial SMC, and mesangial cells (Crosby et al., 1998; Lindahl et al., 1998) . Taken together, these results (along with almost a decade of in vitro work on PDGFRb function in smooth muscle cells) provide strong evidence that PDGFRb signaling is important for vessel formation and maintenance and that a homeostatic mechanism may help maintain the VSMC of the large vessels.
PDGFRa The PDGFRa and PDGF A null mice die either at mid-gestation or perinatally. The early lethality is observed in both the PDGFRa and A null mice (Bostrom et al., 1996; Soriano, 1997) , while some PDGFA null mice die from respiratory failure after birth (Bostrom et al., 1996; Lindahl et al., 1997b) . The PDGFRa mutants do exhibit extensive hemorrhaging and blebbing, but the cause of this phenotype is not well understood. Because the PDGFRa mice have such a variable phenotype, it is dicult to assess the role of the receptor in the vasculature. However, it is unlikely that the PDGFRa has a major role in the VSMC or can be compensating for loss of b in the large vessels because PDGFRa is not normally expressed in VSMC (Orr-Urtreger and Lonai, 1992; Schatteman et al., 1992; Seifert et al., 1998) . For the purpose of this review we will therefore concentrate on the PDGFRb.
Intracellular signaling/cellular function
Many of the signaling molecules associated with the VEGFRs, Tie receptors, and Eph receptors also interact with the PDGFb receptor. These include SFK, PI3 kinase, RasGAP, SHP2, PLCg, and Grb2 among others. Because PDGFR signaling has been recently reviewed (Heldin et al., 1998) , we will only touch on a few key points with regards to PDGFR signaling in VSMC. The eects of PDGF on primary VSMC have been studied for many years. PDGF stimulation can induce several VSMC responses including chemotaxis, proliferation, gene induction, and contraction (Higaki et al., 1996; Inui et al., 1994; Zent et al., 1998) , and (reviewed by Hughes et al., 1996) . Work investigating the role of particular signaling molecules in these responses has led to some surprising results. Recently, immediate early gene responses were compared between a wild type PDGFRb and the F5 PDGFRb (Fambrough et al., 1999) . The F5 PDGFRb receptor has ®ve of the key SH2 domain-binding tyrosines changed to phenylalanine, and in tissue culture cells does not induce DNA synthesis or migration in response to PDGF (Valius and Kazlauskas, 1993) . Unexpectedly, gene induction by the F5 receptor was only reduced in intensity, and a pro®le of gene transcription similar to the wild type receptor gene induction was observed. In addition, we have generated mice expressing a PDGFRb which can no longer bind nor activate PI3-kinase. One would expect the PDGFRb + cells, including the VSMC, to be reduced in their capacity to promote migration and/or cell proliferation (Alimandi et al., 1997; Kundra et al., 1994; Valius and Kazlauskas, 1993) , but unlike the PDGFRb null mice, the mutant mice have no apparent VSMC phenotype. The mice do exhibit the inability to resolve edema, and possibly this is an indication of a loss of cross talk between the b receptor and integrins (Heuchel et al., 1999) . Further analysis of other PDGFRb signaling pathways must be accomplished before a clear picture of how the dierent signaling cascades instruct VSMC in response to PDGF stimulation.
Disruption of Ras signaling pathway perturbs vascular development
As discussed in the previous sections, biochemical and cellular evidence implicates molecules involved in Ras signaling as important modulators of endothelial cell receptor tyrosine kinase function and therefore vascular development. In agreement with these ®ndings, targeted mutation of the genes encoding several of these molecules results in abnormal vascular development. Some of these mutants bear striking resemblance to knock-outs of the endothelial receptor tyrosine kinases and their ligands as well as to each other. In certain cases, a role in vascular development may be masked by functional redundancy between family members as appears to be the case for H-, K-, and N-Ras (Johnson et al., 1997) , or by an essential role in embryonic development which occurs before the onset of vasculogenesis, as may be the case for Grb2 (Cheng et al., 1998) . However, the repeated occurrence of vascular abnormalities in mice harboring targeted mutations in proteins which regulate Ras signaling, including Sos1, Braf, Mek1, SHP-2, and RasGAP indicates that this pathway is pivotal in vascular development.
Targeted mutation of molecules involved in Ras signaling appears to mainly aect post-vasculogenesis events. Sos1 mutants die at mid-gestation and display a range of cardiovascular defects including an enlarged heart, distended pericardium, distention of the major blood vessels, extensive hemorrhage, and pale yolk sacs . The cellular defect which underlies the Sos1 mutant phenotype remains unclear, in part due to the broad expression pattern of this molecule . Mice de®cient in Braf display very similar phenotypic abnormalities to those of Sos1 mutants, and these have been attributed to defective endothelial cell function (Wojnowski et al., 1997) . The blood vessels of Braf mutants are enlarged, abnormally shaped, and are incompletely lined with endothelial cells. Surprisingly, analysis of the vasculature of Braf 7/7 mice revealed an increased number of endothelial precursor cells suggesting enhanced recruitment or proliferation of these cells. The loss of vascular integrity appears to be due to greatly increased apoptosis of dierentiated endothelial cells which at times line the entire circumference of the vessel (Wojnowski et al., 1997) . While the defects observed in these mice are very similar to those lacking Tie2, evidence from cell lines demonstrating the importance of VEGF/VEGFR2 to endothelial survival suggests that defective VEGFR2 signaling may explain, at least in part, the mutant phenotype of mice lacking Braf. Mek1 knock-out mice also die at mid-gestation apparently due to reduced vascularization of the placenta (Giroux et al., 1999) . While vasculogenesis is normal in Mek 1-de®cient mice, a decreased number of endothelial cells is observed at the labyrinthine layer of the developing placenta which may explain the distended appearance of placental blood vessels. Interestingly, the endothelial cells of the Mek1 knockout embryos were restricted to the chorioallantoic region, suggesting an inability to migrate into and invade the labyrinthine region of the placenta. Consistent with the idea that speci®c integrins play a role in angiogenesis, cells derived from Mek 7/7 embryos were markedly impaired in the ability to migrate toward ®bronectin, and migration of wild type cells could be blocked by an a v b 3 speci®c antibody (Giroux et al., 1999) . This observation suggests the intriguing possibility that one point at which cross-talk between VEGFR-2 and a v b 3 occurs is at the level of Mek1. Like the mutants described above, embryos lacking expression of wild type SHP-2 die at midgestation and display defective vascular development, most notably at the yolk sac (Saxton et al., 1997) . Similar to Mek1 mutants vasculogenesis is normal in SHP-2 mutants, however yolk sac blood vessels fail to reorganize into a complex vasculature, remaining in a honeycombed pattern. This suggests that wild type SHP-2 is dispensable for endothelial cell dierentiation, but is required for maturation and reorganization of the vascular network (Saxton et al., 1997) . Considering that SHP-2 has the capacity to aect the Ras signaling pathway by functioning both as an adaptor protein, and as a tyrosine phosphatase, it would be interesting to determine whether an inactivating mutation of the catalytic domain would recapitulate the phenotype of the SHP-2 mutant mice. Consistent with the growing number of studies demonstrating that misregulation of the Ras pathway leads to abnormal vascular development, targeted deletion of RasGAP has also been shown to result in vascular defects leading to lethality at mid-gestation (Henkemeyer et al., 1995) . As with the SHP-2 mutation, mice lacking RasGAP display abnormal yolk sac vasculature due to failure of endothelial cells to reorganize into a vascular network. RasGAP mutants also exhibit a thin dorsal aorta with irregular ventral branching. Furthermore, these mice also exhibit massive apoptosis (Henkemeyer et al., 1995) consistent with the observation in certain tissue culture systems that inappropriate activation of the Ras cascade promotes apoptotic cell death (Ferrari and Green, 1994) .
Taken together, the phenotypes of the mutants described above suggest that, in agreement with data derived from cell lines, Ras-related signaling is essential for normal vascular development. However this signaling cascade is utilized by many dierent cell surface receptors. Therefore it is possible that at least some of the phenotypes observed are not directly due to defects in VEGFR, Tie, or Eph receptor signaling. In order to restrict analysis to endothelial cell receptors, a thorough analysis of receptor autophosphorylation sites is required to identify those sites which are required for Ras activation. In an ideal situation, speci®c autophosphorylation sites that are required for Ras activation will not aect other receptor-mediated signaling events. If so, then mutation of these sites in the mouse may provide an ideal system to assess the contribution of Ras signaling to vascular development directed by the endothelial cell receptor tyrosine kinases.
Cross-talk with cell adhesion receptors
Several lines of evidence suggest that VEGFR-2 does not work alone to mediate endothelial cell function, but instead works in conjunction with adhesion receptors including vascular endothelial (VE)-cadherin, and integrins a v b 3 and a v b 5 during angiogenesis Friedlander et al., 1995; Soldi et al., 1999) . a v b 3 integrin has been identi®ed as an important mediator of survival of nascent blood vessels as it is highly expressed in angiogenic endothelial cells where it suppresses apoptosis promoted by p53 and the cell cycle inhibitor p21 WAF1/CIP1 (Brooks et al., 1994; Stromblad et al., 1996) . a v b 3 may enhance the signaling capacity of VEGFR-2 directly by binding to VEGFR-2 in response to VEGF stimulation (Soldi et al., 1999) . Evidence suggesting that a v b 3 function aects VEGFR-2 signaling comes from the observation that plating of cultured endothelial cells on the a v b 3 ligand vitronectin, but not on other integrin ligands, greatly enhances VEGFR-2 tyrosine phosphorylation, cell proliferation, and migration in response to VEGF. Furthermore, an anti-a v b 3 antibody substantially decreases VEGFinduced proliferation, cell shape changes, and migration without aecting cell adhesion or binding of VEGFR-2 to VEGF (Soldi et al., 1999) .
The a v b 5 integrin also aects VEGFR-2 function but apparently via a mechanism distinct from that of a v b 3 . In corneal or chorioallantoic membrane models VEGF-stimulated angiogenesis is blocked by antibody antagonists to a v b 5 integrin. Interestingly, activation of a v b 5 integrin may contribute to VEGF-induced activation of PKC family members as calphostin C, a protein kinase C inhibitor, blocked angiogenesis potentiated by a v b 5 but not a v b 3 integrin (Friedlander et al., 1995) .
While the exact nature of the connection between VEGFR-2 and integrin signaling remains to be elucidated, it is feasible that integrins act to enhance clustering and dimerization of VEGFR-2 subunits in a manner similar to integrin enhanced activation of the PDGFR b. Ligand-independent tyrosine phosphorylation of the PDGFR b has been shown in cells plated on collagen type I and ®bronectin. This event appears to be due to increased receptor clustering in response to increased mechanical tension or stress exerted on cells upon engagement of integrins by underlying matrix proteins (Sundberg and Rubin, 1996) . Indeed, it has recently been shown that subjecting endothelial cells to shear stress results in clustering and tyrosine phosphorylation of VEGFR-2 (Chen et al., 1999) . It is also possible that the signal transduction mechanisms of VEGFR-2 and integrins converge at a common signaling protein such as MAPK resulting in synergistic activation of this molecule. Enhanced and sustained MAPK activation mediated by multiple receptor tyrosine kinases has been shown to require collaboration with integrins (Eliceri et al., 1998; Miyamoto et al., 1996) .
Strong evidence demonstrating a role for VEcadherin in VEGF-mediated endothelial cell function in vivo comes from a recent paper by describing targeted mutations in the gene encoding VE-cadherin in mice. Targeted mutations that completely disrupted VE-cadherin, or expressed a truncated protein that no longer binds b-catenin, a potential downstream eector, resulted in identical vascular defects which led to lethality by E9.5. The defects were observed at the remodeling/maturation phase of angiogenesis highlighted by impaired sprouting, vessel regression, and reduced endothelial cell survival. Some of these defects may be attributed to weakened stability of adherins junctions. However, in vitro analysis suggests that impaired intracellular signaling downstream of VEGFR-2 leading to decreased endothelial cell survival may also contribute to the VE-cadherin mutant phenotypes. Previously it had been shown that VEGFA, but not the VEGFR-1 speci®c ligand PlGF, results in tyrosine phosphorylation of VE-cadherin (Esser et al., 1998) . Consistent with the idea that VE-cadherin is required to coordinate an anti-apoptotic signal transmitted downstream of VEGFR-2 activation, VEGFA, but not other growth factors tested, promoted survival of wild-type but not VE-cadherin mutant endothelial cells cultured in serum-free medium. Further analysis revealed that VE-cadherin promotes VEGFR-2 signaling by acting as part of a VEGF-induced multicomponent complex with activated VEGFR-2, b-catenin, and PI3K which leads to Akt activation, increased Bcl2 expression and endothelial cell survival .
Conclusions and future perspectives
The recent surge of investigation into mechanisms of signal transduction has provided several important clues as to how the aforementioned RTKs direct distinct functions during vascular development. However, several basic questions remain unanswered. Especially intriguing is how endothelial cells can decipher the signals that are being transmitted simultaneously by multiple cell surface receptors. In addition, a great deal of mystery still surrounds the method of activation and the function of Tie1.
Targeted deletion of Tie1 demonstrates that it is required for vascular integrity, but how is it activated and why have intense eorts to identify its ligand been fruitless? Possibly, Tie1 functions as a co-receptor, activated only in the presence of another cell surface molecule. This would stress the importance of looking at the RTKs not only as single entities that transmit linear signals, but also as components of an integrated signaling complex. Indeed, initial forays into the issue of receptor cross-talk have shown that the RTKs do not work alone, but act as part of multi-protein signaling complexes with other cell surface receptors such as the integrins and cadherins. To go one step further, we also need to traverse beyond the membrane into the nucleus to study the genes that are induced by the surface receptors. These genes will provide information about dierentiation and intercellular communication.
The challenge for vascular biologists is to elucidate how multiple signals to and from a single cell result in complex multicellular interactions that ultimately form the vasculature. While understanding intracellular signaling and gene induction is one step, comprehending the mechanisms of intercellular communication (both between similar cell types and dierent cell types) will be a formidable task. For example, little is known about what controls vessel size, or how the density of SMC is determined. How do SMC form dense layers around arteries, while only sparsely coating veins? The interactions between endothelial cells and SMC are likely to be very speci®c, and we have only begun to scratch the surface towards understanding this level of cellular communication. Finally, it is important to translate what we have learned about the developing vasculature to the adult system. Certainly, some of the molecules play similar roles, but there may be unique circumstances that apply only in the adult. The further investigation of signaling events involved in vascular formation, maturation, and maintenance will help to elucidate these complex relationships.
